Literature DB >> 20736250

A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100.

Alison Taylor1, Graham Bayly, Kunjan Patel, Laura Yarram, Maggie Williams, Julian Hamilton-Shield, Steve E Humphries, Gail Norbury.   

Abstract

Autosomal dominant hypercholesterolaemia is genetically heterogeneous, but most commonly (approximately 93%) caused by mutations in low-density lipoprotein receptor (LDLR), where the disease is known as familial hypercholesterolaemia (FH), or apolipoprotein B-100 (APOB) (approximately 5.5%), where the disease is known as familial defective APOB (FDB), while in approximately 2% of patients the mutation is in the proprotein convertase subtilisin/kexin type 9 gene. Homozygous FH having inheritance of two LDLR mutations is a rare but recognized syndrome associated with an extreme hypercholesterolaemia and early-onset coronary artery disease. We present a 15-year-old girl with untreated total cholesterol levels of 8.8 mmol/L who was heterozygous for both the LDLR p.Leu479Pro and APOB p.Arg3527Gln mutation. Cascade testing confirmed the paternal origin of the LDLR mutation and revealed a maternal diagnosis of FDB. This case provides further evidence that the combined effect of an LDLR and an APOB mutation give rise to a phenotype more severe than either mutation alone and is more severe than homozygous FDB, but less severe than homozygous FH. It also highlights the need to consider the presence of additional mutations in families where relatives have varying phenotypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736250     DOI: 10.1258/acb.2010.010089

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  7 in total

Review 1.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

2.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.

Authors:  Pradeep Natarajan; Nina B Gold; Alexander G Bick; Heather McLaughlin; Peter Kraft; Heidi L Rehm; Gina M Peloso; James G Wilson; Adolfo Correa; Jonathan G Seidman; Christine E Seidman; Sekar Kathiresan; Robert C Green
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

Review 3.  Genetics of familial hypercholesterolemia.

Authors:  Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 4.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

5.  A Rare Double Heterozygous Mutation in Low-Density Lipoprotein Receptor and Apolipoprotein B-100 Genes in a Severely Affected Familial Hypercholesterolaemia Patient.

Authors:  Lilla Juhász; István Balogh; László Madar; Beáta Kovács; Mariann Harangi
Journal:  Cureus       Date:  2020-12-20

6.  New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia.

Authors:  Sandy Elbitar; Delia Susan-Resiga; Youmna Ghaleb; Petra El Khoury; Gina Peloso; Nathan Stitziel; Jean-Pierre Rabès; Valérie Carreau; Josée Hamelin; Ali Ben-Djoudi-Ouadda; Eric Bruckert; Catherine Boileau; Nabil G Seidah; Mathilde Varret; Marianne Abifadel
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

7.  Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients.

Authors:  Hsin Tung; Hsueh-Ju Lin; Po-Lin Chen; Tsai-Jung Lu; Pei-Pei Jhan; Jun-Peng Chen; Yi-Ming Chen; Chen-Chin Wu; Yung-Yang Lin; Tzu-Hung Hsiao
Journal:  Aging (Albany NY)       Date:  2021-07-27       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.